| Abstract |
Abstract Objective: To analyze the effects of quetiapine fumarate combined with sodium valproate on cognitive function and inflammatory oxidation factors in patients with bipolar disorder. Methods: A total of 102 patients with bipolar disorder in our hospital from February 2021 to February 2023 were selected as the study objects, and were divided into 2 groups with 51 cases in each group by random number table method. The control group was treated with sodium valproate sustained-release tablets, and the study group was treated with quetiapine fumarate. After 8 weeks of treatment, the clinical efficacy, manic and depressive symptom control, cognitive function, inflammatory oxidation factors, and adverse reactions were compared between the two groups. Results: The total effective rate of the study group was higher than that of the control group (96.08%>82.35%) (P<0.05). After treatment, the Seashle-lavenson mania scale (BRMS) score and Hamilton depression self-rating scale were evaluated. HAMD scores were lower than those in control group (P<0.05). After treatment, the scores of orientation, memory, attention, calculation, recall and language ability in the study group were higher than those in the control group (P<0.05). After treatment, the patients in the study group had Interleukin-1β (IL-1β), Interleukin-4 (IL-4), and Tumor necrosis factor-α (tumor necrosis factor-α). The levels of TNF-α and Malondialdehyde (MDA) were lower than those in control group, and Superoxide dismutase (SOD) and Glutathione peroxidase, respectively. The levels of GSH-Px were higher than those of control group (P<0.05). The incidence of adverse events was compared between the two groups (P>0.05).Conclusion: Quetiapine fumarate combined with sodium valproate is effective in the treatment of patients with bipolar disorder, which can effectively control the onset of manic and depressive symptoms, improve cognitive function, regulate the level of inflammatory oxidation factors, improve treatment effect, and have high safety.
|